ArticleAntimicrobial agents and chemotherapy2015
Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis.Journal of viral hepatitis · 2021Pooled it
- Extra-Hepatic Manifestations of Hepatitis E Virus (HEV): A Narrative Review on Meningoencephalitis.Life (Basel, Switzerland) · 2026Review
- Characterization of virus‒host recombinant variants of the hepatitis E virus.Journal of virology · 2024Article
- Kinetics of Hepatitis E Virus Infections in Asymptomatic Persons.Emerging infectious diseases · 2024Article
- Risk Factors for Hepatitis E Virus Infection and Eating Habits in Kidney Transplant Recipients.Pathogens (Basel, Switzerland) · 2023Article
- Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.Archives of virology · 2023Article
- Article
- Article
- Quasispecies Fitness Partition to Characterize the Molecular Status of a Viral Population. Negative Effect of Early Ribavirin Discontinuation in a Chronically Infected HEV Patient.International journal of molecular sciences · 2022Article
- Two mutations in the ORF1 of genotype 1 hepatitis E virus enhance virus replication and may associate with fulminant hepatic failure.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Immunization with Virus-Like Particle Vaccine Protects Rabbits against Hepatitis E-3 Virus Infection.Viruses · 2022Article
- Development of Recombinant Infectious Hepatitis E Virus Harboring the nanoKAZ Gene and Its Application in Drug Screening.Journal of virology · 2022Article
- Viral hepatitis in 2021: The challenges remaining and how we should tackle them.World journal of gastroenterology · 2022Review
- Article
- Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients.BMC infectious diseases · 2020Article
- Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections.Journal of clinical medicine · 2020Review
- Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E.International journal of environmental research and public health · 2020Article
- Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients.Microorganisms · 2019Article
- Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing.Antimicrobial agents and chemotherapy · 2019Article
- Hepatitis E Virus Shows More Genomic Alterations in Cell Culture than In Vivo.Pathogens (Basel, Switzerland) · 2019Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients (P = 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.